Market
Which region will first implement Lenacapavir by end of 2025?
2
Resolution / Starting Odds
Asia • 25%
North America • 25%
Europe • 25%
Africa • 25%
Official announcements from pharmaceutical companies or health organizations
Story
Lenacapavir: New Injectable HIV Drug Offers 96-100% Efficacy with Twice-Yearly Dosing, Recognized as Scientific Breakthrough
Dec 30, 2024, 01:30 PM
A new injectable antiretroviral drug, Lenacapavir, has been recognized as a potential breakthrough in the fight against HIV and AIDS. According to reports, it boasts an efficacy rate of 96-100% and offers a twice-yearly dosing schedule, which could significantly enhance treatment accessibility and adherence. This innovation has been highlighted by the journal 'Science' as a scientific breakthrough of the year, with the potential to curb new HIV infections globally. Discussions around its availability and implementation are ongoing, as stakeholders consider the implications of this advancement in HIV prevention and treatment.
View original story
Similar markets
Southeast Asia • 25%
South America • 25%
Other • 25%
Sub-Saharan Africa • 25%
Sub-Saharan Africa • 25%
South Asia • 25%
Southeast Asia • 25%
Latin America • 25%
Other • 25%
United States • 25%
European Union • 25%
Africa • 25%
Asia • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
Europe • 25%
North America • 25%
Africa • 25%
Sub-Saharan Africa • 25%
Latin America • 25%
South Asia • 25%
Southeast Asia • 25%
European Union • 25%
Other • 25%
South Africa • 25%
United States • 25%
Other • 25%
United States • 25%
South Africa • 25%
India • 25%
1-4 countries • 25%
10-14 countries • 25%
15 or more countries • 25%
5-9 countries • 25%
South Africa • 25%
USA • 25%
UK • 25%
Other • 25%
Europe • 25%
North America • 25%
South America • 25%
Asia • 25%